US Food and Drug Administration Approves REVLIMID® (lenalidomide) for the ... National Post ... approval was based on the results of MCL-001, a phase II, multi-center, single arm, open label study evaluating lenalidomide in 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or ... |
